The Medicines Company (MDCO) insider have most recently took part in a trading activity. On Nov 30, 2017 Panayiotopoulos Paris, Director bought 3,215 shares having total worth of $99,569 at the price of $30.97 per share, following the transaction a total of 6,452 shares owned by Panayiotopoulos Paris.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 5 times by insiders. In 2 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of The Medicines Company (MDCO) traded down 3.88% on Nov 30, 2017, hitting $29. 1,966,723 shares of the company’s stock traded hands. The Medicines Company has a 52 week low of $28.3 and a 52 week high of $54.7. The company’s market cap is $2,810 million.
The Medicines Company (MDCO) last announced its earnings results on Oct 25, 2017. The company reported 0.00 earnings per share (EPS) for the quarter, higher than the consensus estimate of -1.46 by $1.46., compared to the consensus estimate of $24 million. During the same quarter in the previous year, the company posted -0.64 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.
|earnings per share||0.00||-1.02||-1.05||-1.19||-0.64||-0.62||-1.03||-0.88||-0.82||-0.65|
Medicines was incorporated in Delaware on July 31, 1996. It is a global biopharmaceutical company focused on saving lives, alleviating suffering and improving the economic efficiency of the world’s hospitals. It has four marketed products, Angiomax(bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a topical human recombinant thrombin. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. It also has a pipeline of acute and intensive care hospital products in development, including four late-stage development product candidates, cangrelor, oritavancin, MDCO-157 and IONSYS TM (fentanyl iontophoretic transdermal system), and early stage development product candidates, MDCO-216 and ALN-PCS02 and ALN-PCSsc of its ALN-PCS program. In addition to these products and product candidates, it has a portfolio of ten generic drugs. The Company also co-promotes the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States, as part of its global collaboration agreement with AstraZeneca LP, or AstraZeneca. Angiomax, Recothrom, Cleviprex, ready-to-use Argatroban and its products in development, their stage of development, their mechanism of action and the indications for which they have been approved for use or which they are intended to address. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018